| Field | Specification |
|---|---|
| Target | |
| Alternative names | Transforming growth factor beta-2;TGF-beta-2;BSC-1 cell growth inhibitor;Cetermin;Glioblastoma-derived T-cell suppressor factor;G-TSF;Polyergin;Latency-associated peptide;LAP;TGFB2; |
| Gene ID | |
| UniProt # | |
| Reactivity | |
| Applications | |
| Immunogen | Expression system for standard: NS0; Immunogen sequence: A303-S414 |
| Expression system | |
| Expression region | |
| Assay type | |
| Sample type(s) | Cell Culture Supernatant, Serum, Plasma |
| Sensitivity | |
| Detection range | |
| Assay time | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Assay Principle
This sandwich ELISA quantifies human transforming growth factor beta-2 proprotein (gene TGFB2) in cell culture supernatants, serum and plasma (heparin, EDTA, citrate). Strips are pre-coated with a capture antibody. After the sample is added, a biotinylated detection antibody binds the captured protein, and an avidin–biotin–peroxidase complex supplies the enzyme. TMB develops color in proportion to the bound target; the reaction is stopped and read at 450 nm, and concentrations are read from the standard curve.
TGF-β2 is a member of the TGF-β cytokine family, secreted in a latent form bound to its latency-associated peptide. After activation it signals through TGF-β receptors and SMAD proteins to regulate cell growth, differentiation and matrix production, and it has well-established roles in heart, craniofacial and eye development.
Kit Components
| Anti-Human TGFB2 Pre-coated 96-well strip microplate | 1 plate (96 wells) |
|---|---|
| Human TGFB2 Standard | 2 vials, 10 ng/tube |
| Human TGFB2 Biotinylated antibody (100x) | 100 µL |
| Avidin-Biotin-Peroxidase Complex (100x) | 100 µL |
| Sample Diluent | 30 mL |
| Antibody Diluent | 12 mL |
| Avidin-Biotin-Peroxidase Diluent | 12 mL |
| Color Developing Reagent (TMB) | 10 mL |
| Stop Solution | 10 mL |
| Wash Buffer (25x) | 20 mL |
| Adhesive plate sealers | 4 |
Also required (not supplied): microplate reader for 450 nm; incubator; automated plate washer (optional); precision pipettes for 0.5 µL through 1 mL volumes of aqueous solutions; multichannel pipettes (recommended for many samples); deionized or distilled water; 500 mL graduated cylinders; test tubes for dilution.
Kit components are not sold separately.
Performance Data
| Species | Human |
|---|---|
| Sample types | Cell culture supernatants, serum and plasma (heparin, EDTA, citrate) |
| Assay range | 31.2 pg/mL–2,000 pg/mL |
| Sensitivity | <10 pg/mL |
| Standard | Recombinant human TGFB2 (Ala303–Ser414), expressed in NS0 |
| Cross-reactivity | None detected against related proteins in supplier testing |
| Intra-assay CV | 4.8–7.9% (3 samples, n = 16 each) |
| Inter-assay CV | 4.8–9.3% (3 samples, n = 24 each) |
| Format | 96 wells, removable strips |
Sample dilution: start at 1:1. In the supplier’s tests, serum and plasma samples measured 0–115 pg/mL.
Example standard curve (OD450, pg/mL): 0 = 0.026; 31.2 = 0.082; 62.5 = 0.14; 125 = 0.269; 250 = 0.491; 500 = 0.917; 1000 = 1.443; 2000 = 2.122. Run a new standard curve on every plate.
Storage & Handling
Store at 4 °C for up to 6 months or −20 °C for up to 12 months. Avoid repeated freeze–thaw cycles. Ships on gel ice and tolerates up to 3 days at room temperature; freeze on arrival.
Safety
Sample data
| Concentration (pg/ml) | 0 | 31.2 | 62.5 | 125 | 250 | 500 | 1000 | 2000 |
| O.D. | 0.026 | 0.082 | 0.14 | 0.249 | 0.476 | 0.917 | 1.743 | 3.022 |
Intra/inter assay consistency
| Intra-Assay Precision | Inter-Assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 16 | 16 | 16 | 24 | 24 | 24 |
| Mean (pg/ml) | 49 | 188 | 820 | 48 | 188 | 864 |
| Standard deviation | 3.87 | 13.53 | 39.36 | 4.46 | 15.41 | 41.47 |
| CV (%) | 7.9% | 7.2% | 4.8% | 9.3% | 8.2% | 4.8% |
Kit components
Description|Quantity Pre-coated 96-well strip microplate|1 Standard|2 vials Biotinylated antibody (100x)|100ul Avidin-Biotin-Peroxidase Complex (100x)|100ul Sample Diluent|30ml Antibody Diluent|12ml Avidin-Biotin-Peroxidase Diluent|12ml Color Developing Reagent (TMB)|10ml Stop Solution|10ml Wash Buffer (25x)|20ml Adhesive plate sealers|4Materials required but not provided
- Microplate Reader capable of reading absorbance at 450nm.
- Incubator.
- Automated plate washer (optional).
- Pipettes and pipette tips capable of precisely dispensing 0.5 µl through 1 ml volumes of aqueous solutions.
- Multichannel pipettes are recommended for large amount of samples.
- Deionized or distilled water.
- 500ml graduated cylinders.
- Test tubes for dilution.
Activating reagent preparation
TGF beta 2 is mostly contained as inactive form in samples, please activate it before assay. Don't activate recombinant TGF beta 2.
Solution A: 1N HCI: add 8.33ml of 12N HCI into 91.67ml of H2O.
Solution B: 1.2N NaOH/0.5M HEPES: add 12ml of 10N NaOH and 11.9g HEPES into 75ml of H2O, add H2O to adjust volume to 100ml.
Sample activation procedure
Activate the sample
Cell culture supernatants: add activating reagent pro rata, i.e. add 20μl of Solution A into 100μl of sample, 10 min later, add 20μl of Solution B. PH 7.0-7.6.
Serum, plasma(heparin, EDTA or citrate): add activating reagent pro rata, i.e. add 20μl of Solution A into 40μl of sample, 10 min later, add 20μl of Solution B. PH 7.0-7.6.
It is unnecessary to activate the recombinant TGF-beta 2.
Sample was diluted partly after adding activating reagent, so please pay attention to this when calculate target protein concentration.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Chenlong He et al. (2025) Magnetic Nanoactuator-Protein Fiber Coated Hydrogel Dressing for Well-Balanced Skin Wound Healing and Tissue Regeneration. ACS Nano. 10.1021/acsnano.4c15647
Jiawei Huang et al. (2022) Human pluripotent stem cell-derived ectomesenchymal stromal cells promote more robust functional recovery than umbilical cord-derived mesenchymal stromal cells after hypoxic-ischaemic brain damage. Theranostics. 10.7150/thno.57234
Chuan Wang et al. (2023) Circulating Tfr/Tfh cell imbalance may contribute to the immunopathogenesis of pemphigus. Journal of the European Academy of Dermatology and Venereology. 10.1111/jdv.19338
Lu Chang et al. (2025) Bufalin inhibits immune escape in metastatic colorectal cancer by regulating M2 macrophage polarization. Apoptosis. 10.1007/s10495-025-02107-y
Jinghua Wang et al. (2024) Pro-fibrotic effect of the susceptible gene PCSK5 in vascular fibrosis of Takayasu arteritis via TGF-β and SMAD3 signaling pathway activation. Journal of Autoimmunity. 10.1016/j.jaut.2024.103277
Tang Donghao et al. (2024) Mechanism of bufalin inhibition of colon cancer liver metastasis by regulating M2-type polarization of Kupffer cells induced by highly metastatic colon cancer cells. Apoptosis. 10.1007/s10495-023-01930-5
Das Dayasagar et al. (2023) Dominance and improved survivability of human γδT17 cell subset aggravates the immunopathogenesis of pemphigus vulgaris. Immunologic Research. 10.1007/s12026-023-09413-0
Haitao Yang et al. (2025) TREM2-mediated neuroinflammatory response is involved in AgNPs-induced ferroptosis in HMC3 cells. Neurotoxicology. 10.1016/j.neuro.2025.103326
Ying Yu et al. (2023) A pilot study of S100A4, S100A8/A9, and S100A12 in dilated cardiomyopathy: novel biomarkers for diagnosis or prognosis?. ESC Heart Failure. 10.1002/ehf2.14605
A. Işılay Özdoğan et al. (2018) Development and in vitro evaluation of chitosan based system for local delivery of atorvastatin for treatment of periodontitis. European Journal of Pharmaceutical Sciences. 10.1016/j.ejps.2018.08.037
